VENKATASUBRAMANIAN BASKARARAJAN: Open Payments
NPI 1407052228 · HATTIESBURG, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,441 in 81 payments from 11 companies in 2025. Trend: 2023 $794 · 2024 $874 · 2025 $1,441
Food & beverage: $1,441
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 17 | $284 |
| Janssen Pharmaceuticals, Inc | 12 | $212 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $192 |
| ABBVIE INC. | 12 | $154 |
| Alkermes, Inc. | 9 | $137 |
| Lundbeck LLC | 6 | $116 |
| Axsome Therapeutics, Inc. | 5 | $100 |
| Vanda Pharmaceuticals Inc. | 3 | $83 |
| Otsuka America Pharmaceutical, Inc. | 3 | $57 |
| Neurocrine BioSciences, Inc. | 2 | $55 |
Products named: COBENFY, INVEGA SUSTENNA, CAPLYTA, VRAYLAR, ARISTADA, ABILIFY ASIMTUFII, Auvelity, FANAPT.
Industry payments across MS — which companies pay providers there.
